

April 01, 2022

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Ltd.
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub.: Appointment of Mr. Narotam Kumar Juneja as Non-Executive Non-Independent Director

Re: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company has, on the recommendation of Nomination and Remuneration Committee, appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022.

In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we have got the confirmation from Mr. Narotam Kumar Juneja that he is not debarred from accessing the capital market and / or restrained from holding the office of Director by virtue of any order of SEBI or any other such authority.

The details as required to be disclosed under the aforesaid Regulation 30 read with Clause 7 of Para A of Annexure I of SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09 September, 2015 is enclosed as **Annexure - A** to this letter.

You are requested to take the above information on record.

Thanking you,

Sincerely yours,

For Panacea Biotec Ltd.



Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com

Annexure - A

S. No.	Particulars	Details
a)	Reason for change viz. appointment, resignation, removal, death or otherwise	Mr. Narotam Kumar Juneja (DIN: 01204817) has been appointed as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company.
b)	Date of appointment and term of appointment	Date of Appointment: April 01, 2022. Mr. Narotam Kumar Juneja shall hold the office as an additional director till the conclusion of the next Annual General Meeting (“AGM”) of the Company or the last date on which the AGM should have been held, whichever is earlier.
c)	Brief Profile	Mr. Narotam Kumar Juneja, aged about 66 years, has done Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations. He has rich experience of over 40 years in pharmaceutical operations (including in the Company) and has executed multiple internationally approved projects worth \$150M+ for reputed companies. He has earlier been associated with the Company as Vice President Operations & Projects during 2003-2006 and again as Chief Operating Officer during 2010-2014. He has also worked at senior positions with Dawa Group Ltd., Kenya and several other companies in India including Unichem Laboratories, Ranbaxy Laboratories, Systopic India and Dabur India.
d)	Disclosure of relationship between Directors	Mr. Narotam Kumar Juneja is not related to any other Director of the Company.



Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com